Monofer Innrennslislyf, lausn 100 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

monofer innrennslislyf, lausn 100 mg/ml

pharmacosmos a/s* - ferricum derisomaltosum inn - innrennslislyf, lausn - 100 mg/ml

Vildagliptin / Metformin hydrochloride Accord Evrópusambandið - íslenska - EMA (European Medicines Agency)

vildagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - sykursýki, tegund 2 - lyf notuð við sykursýki - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) Evrópusambandið - íslenska - EMA (European Medicines Agency)

icandra (previously vildagliptin / metformin hydrochloride novartis)

novartis europharm limited - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).

Vectormune FP ILT + AE Evrópusambandið - íslenska - EMA (European Medicines Agency)

vectormune fp ilt + ae

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - kjúklingur - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Vectormune FP ILT Evrópusambandið - íslenska - EMA (European Medicines Agency)

vectormune fp ilt

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - kjúklingur - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.

Busol Stungulyf, lausn 0,004 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

busol stungulyf, lausn 0,004 mg/ml

t.p. whelehan son & co. ltd. - buserelinum acetat - stungulyf, lausn - 0,004 mg/ml